Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 450 of 2026 entries
View as:

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Phase: N/A Priority: Normal
NCT ID: NCT00875979 Org: User:
Start: 05/31/09 End: 08/31/11 Due: 08/31/12

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01069627 Org: User:
Start: 12/31/06 End: 07/31/09 Due: 07/31/10

A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants

Phase: N/A Priority: Normal
NCT ID: NCT01767623 Org: User:
Start: 08/20/13 End: 04/20/17 Due: 04/20/18

A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy

Phase: N/A Priority: Normal
NCT ID: NCT02624141 Org: User:
Start: 04/30/06 End: 12/31/09 Due: 12/31/10

A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01209221 Org: User:
Start: 09/30/10 End: 10/31/11 Due: 10/31/12

A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00022672 Org: User:
Start: 01/31/01 End: 10/31/09 Due: 10/31/10

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01974258 Org: User:
Start: 02/28/14 End: 07/31/14 Due: 07/31/15

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00800176 Org: User:
Start: 01/22/09 End: 10/28/09 Due: 10/28/10

A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT00451906 Org: User:
Start: 08/31/06 End: 06/30/09 Due: 06/30/10

An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01337388 Org: User:
Start: 08/31/10 End: 10/31/13 Due: 10/31/14

AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01777932 Org: User:
Start: 12/31/07 End: 03/31/12 Due: 03/31/13

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00883779 Org: User:
Start: 04/30/09 End: 12/31/14 Due: 12/31/15

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Phase: N/A Priority: Normal
NCT ID: NCT02367794 Org: User:
Start: 06/11/15 End: 02/17/21 Due: 02/17/22

A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01308723 Org: User:
Start: 03/31/11 End: 01/31/12 Due: 01/31/13

A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users

Phase: N/A Priority: Normal
NCT ID: NCT01438749 Org: User:
Start: 10/31/11 End: 05/31/12 Due: 05/31/13

A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02006667 Org: User:
Start: 01/31/01 End: 01/31/10 Due: 01/31/11

A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081

Phase: N/A Priority: Normal
NCT ID: NCT06809608 Org: User:
Start: 02/13/25 End: 06/17/25 Due: 06/17/26

A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02576964 Org: User:
Start: 01/31/05 End: 11/30/08 Due: 11/30/09

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06004245 Org: User:
Start: 01/25/24 End: 05/31/27 Due: 05/31/28

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05415215 Org: User:
Start: 07/05/22 End: 12/31/25 Due: 12/31/26

A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04023994 Org: User:
Start: 08/03/19 End: 07/17/20 Due: 07/17/21

A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

Phase: N/A Priority: Normal
NCT ID: NCT02075840 Org: User:
Start: 08/19/14 End: 04/09/25 Due: 04/09/26

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03677154 Org: User:
Start: 05/23/19 End: 08/07/25 Due: 08/07/26

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01185873 Org: User:
Start: 02/28/11 End: 12/31/13 Due: 12/31/14

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05945927 Org: User:
Start: 09/13/23 End: 09/30/25 Due: 09/30/26